LiDCO Group Plc

("LiDCO" or the "Company")

Simultaneous monitoring of blood flow and depth of anesthesia will make it easier to optimize patients during surgery

LiDCO Group Plc (AIM: LID), the cardiovascular monitoring company, today announces the results of a study which looked at changes in blood flow and depth of anesthesia in patients undergoing vascular surgery.  The study showed that simultaneously monitoring these parameters helps ensure that only the optimal amount of anesthetic drug is given to prevent awareness during surgery. This minimizes falls in blood pressure and flow, which are then more easily and quickly corrected with fluid and drugs administration guided through use of the LiDCOrapid monitor. The results of the study were presented by Dr B Purushothaman, Dr David Green and Dr Terry O'Brien at Kings College Hospital, London on Friday 30 April 2010.

Anesthetic overdose can cause excessively low blood pressure and even circulatory failure. The use of hemodynamic monitoring to prevent or limit oxygen debt during surgery has been shown to reduce complications and hospital length of stay. The researchers measured hemodynamic changes in 46 patients as anaesthetic drugs were administered immediately prior to surgery. Hemodynamic changes and depth of anaesthesia were recorded with LiDCO's LiDCOrapid monitor and Covidien's BiSpectral Index (BIS). The study found that as the anesthetic is administered to a patient, blood pressure falls dramatically, usually because the blood flow is reduced. The depth of anesthesia as measured by BIS, correlated well with changes in the blood flow and blood pressure. The results demonstrated that the coordinated monitoring of both anesthesia depth and the circulatory effects makes optimizing blood flow parameters to prevent oxygen debt during major surgery simpler.

Dr Terry O'Brien, CEO of LiDCO, commented:  "More comprehensive multiparameter monitoring of high risk surgery patients will be a significant step forward in care. This study has shown that integrating data regarding the depth of anesthesia, blood flow and fluid requirements will allow more efficient control of the potentially dangerous and life threatening  hemodynamic changes seen during surgery. LiDCO intend to combine these two technologies in single monitoring display on the LiDCOrapid monitor platform. This will help to make it easier to prevent complications or awareness in patients, that could arise from administering anesthetic drugs in too high or low a dosage."

- ENDS -

For more information please contact:

Media enquiries

About LiDCO Group Plc

LiDCO is a supplier of minimally invasive hemodynamic monitoring equipment and disposables to hospitals. These products are used primarily for the management of adult hospital patients requiring critical care or at major cardiovascular risk. LiDCO's computer-based technology can significantly reduce the complications (particularly infections) and costs associated with major surgery. The technology was invented in the Department of Applied Physiology based at St Thomas' Hospital, London. LiDCO is based in the UK and its shares are traded on AIM. For more information please see www.lidco.com.

The Company's sales office is in Cambridge, its manufacturing facility / general administration base is in Hoxton, London, and its current products are:

* LiDCOplus is a computer-based platform monitor used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid-volume responsiveness (PPV% and SVV%)

* LiDCOrapid: our new cardiac output monitor designed specifically for use in the Operating Theatre for fluid and drug management. The monitor enables acute-care physicians to get accurate and immediate feedback on the patient's fluid and hemodynamic status - a key measure of overall well-being both during and after surgery.  The benefits are:

* LiDCO single-patient-use disposables used in conjunction with the LiDCOplus and LiDCOrapid.

* LiDCOview: an easy-to-use graphical display of historical LiDCOplus and LiDCOrapid hemodynamic data.

 LiDCO's Distribution Network:

The Company sells via its own direct sales force to hospitals in the UK, and in export markets predominantly through a worldwide network of speciality critical care and anesthesia distributors.